SXSaiyare Xuekelati

Saiyare Xuekelati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saiyare Xuekelati has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Buluhan Mm Halan

    Second Department of Comprehensive Internal Medicine of People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

    1 shared publication
  • Hongmei Wang

    Second Department of Comprehensive Internal Medicine of People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

    1 shared publication
  • Jiangdong Wu

    Key Laboratory of Xinjiang Endemic and Ethnic Diseases Cooperated by Education Ministry with Xinjiang Province, Shihezi University, Shihezi, China

    1 shared publication
  • Jiangdong Wu

    Key Laboratory of Xinjiang Endicand Ethnic Diseases Cooperated By Education Ministry with Xinjiang Province, Shihezi University, Shihezi, China

    1 shared publication
  • Jinling Mm Liu

    Second Department of Comprehensive Internal Medicine of People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

    1 shared publication
  • Kejian Liu

    Department of Cardiology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China

    1 shared publication

Latest Publications

  • Open Access

    TWEAK/Fn14 hypomethylation and higher plasma TWEAK and TNF-α levels are related to sarcopenic obesity in community-dwelling elderly in Xinjiang

    by Lingling Ma, Zhuoya Maimaitiwusiman, Saiyare Xuekelati, Buluhan Mm Halan, Jinling Mm Liu, Hongmei Wang

    Sarcopenic obesity is a primary factor contributing to the decline in the quality of life among the elderly in our country. Studies have shown that hypomethylation of tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) is associated with sarcopenia. Our research primarily explores whether this mechanism also affects the progression of sarcopenic obesity. A total of 120 subjects were grouped into the case (sarcopenic obesity) and control (non-sarcopenic and nonobese) groups, with 60 subjects in each group based on power test (medium effect size, power = 80%). Bisulfite sequencing was used to assess the methylation status of TWEAK/Fn14 in these subjects. ELISA was employed to measure the plasma concentrations of TWEAK, tumour necrosis factor-alpha (TNF-α), interleukin (IL)-4, IL-6, and IL-10. SPSS 17.0 and R software was used for statistical analysis, employing multiple logistic regression to adjust for residual confounding factors, and Student t tests for difference analysis. Compared to the case group, the control group had higher methylation levels at CpG20, CpG30 sites in TWEAK (P = .043 for both). Additionally, the control group showed higher methylation level at CpG25 site in Fn14 (P = .025). After adjusting for hypertension, diabetes, triglyceride levels, gender, and age, Student t tests covariance confirmed significant differences in the enrichment levels of TWEAK, TNF-α, IL-10, and IL-4 of patients in case group (P TWEAK = .017, P TNF-α < .001, P IL-10 = .010, P IL-4 = .016). Multivariate logistic regression analysis revealed that higher plasma levels of TWEAK and TNF-α were significantly associated with the incidence of sarcopenic obesity (odds ratios = 1.024, 95% confidence interval = 1.006–1.042; odds ratios = 2.537, 95% confidence interval = 1.697–3.793). This evidence suggested that hypomethylation of TWEAK/Fn14 also affected sarcopenic obesity progression. Increased enrichment of TWEAK and TNF-α in plasma, along with hypomethylation of TWEAK and Fn14, promotes the occurrence of sarcopenic obesity may affect occurrence of sarcopenic obesity.


  • Open Access

    Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia

    by Kejian Liu, Saiyare Xuekelati, Yue Zhang, Yin Yin, Yue Li, Rui Chai, Xinwei Li, Yi Peng, Jiangdong Wu, Xiaomei Guo

    An elevated level of homocysteine (Hcy) in the blood is designated hyperhomocysteinaemia (Hhcy) and is regarded as a strong risk factor for the development of atherosclerosis (ATH), although the association remains controversial. Considered to be essential gene expression regulators, micro-RNAs (miRNAs) modulate cardiovascular disease development and thus can be regarded as potential biomarkers and therapeutic targets in atherosclerosis. The aim of the current study is to investigate the expression levels of atherosclerosis-associated miR-143 and miR-145 in Hhcy patients and predict the progress of atherosclerosis in Hhcy patients. A total of 100 participants were enrolled and included normal control subjects (NC = 20), hyperhomocysteinaemia alone subjects (Hhcy = 25), hyperhomocysteinaemia and carotid artery atherosclerosis combined subjects (Hhcy + ATH = 30) and patients with standalone carotid artery atherosclerosis (ATH = 25). Plasma Hcy, supplementary biochemical parameters and carotid artery ultrasonography (USG) were measured in all participants. MicroRNA expression levels in the peripheral blood were calculated by real-time reverse transcription-polymerase chain reaction (qRT-PCR). The correlations of miR-143 and miR-145 with Hcy, blood lipid parameters and carotid artery atherosclerotic plaques were evaluated using Pearson’s correlation coefficients. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the capacities of miR-143 and miR-145 for the detection of Hhcy and atherosclerosis patients. MiR-143 and miR-145 exhibited trends towards significance with stepwise decreases from the NC to Hhcy groups and then to the Hhcy + ATH and ATH groups. Similar results were observed in the carotid artery plaque group (Hhcy + ATH and ATH grups) compared with the no-plaque group (NC and Hhcy groups). The miR-143 expression level exhibited significant negative correlations with Hcy, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c). The miR-145 expression level exhibited significant negative correlations with Hcy, TC, triglyceride (TG) and LDL-c. MiR-143 and miR-145 exhibited the greatest area under the curves (AUCs) (0.775 and 0.681, respectively) for the detection of every Hhcy patient, including those in the Hhcy and Hhcy + ATH groups, from among all subjects. The results indicated that the levels of atherosclerosis-associated circulating miR-143 and miR-145 are linked to Hhcy. MiR-143 may be used as a potential non-invasive biomarkers of Hhcy and thus may be helpful in predicting the progress of atherosclerosis in Hhcy patients.